홈MCP워크벤치Skills
홈워크벤치알림마이페이지
llms.txt · MCP 가이드개인정보처리방침 · 이용약관 · 지원v1.8.0
  1. 홈
  2. /반응

1-{2-[{6-[(3-Chloro-4-{methyl[3-(methylamino)propyl]carbamoyl}phenyl)amino]hexanoyl}(methyl)amino]ethyl}piperidin-4-yl biphenyl-2-ylcarbamate → 1-(2-{[6-({4-[{3-[({[(2S)-1'-{2-[(5R)-3-[3,5-Bis(trifluoromethyl)benzoyl]-5-(4-fluorophenyl)-1,3-oxazolidin-5-yl]ethyl}-2,3-dihydrospiro[indene-1,4'-piperidin]-2-yl]oxy}acetyl)(methyl)amino]propyl}(methyl)carbamoyl]-3-chlorophenyl}amino)hexanoyl](methyl)amino}ethyl)piperidin-4-yl biphenyl-2-ylcarbamate trihydrochloride

HRID 446578
노트
인쇄 미리보기

반응식

HRID 446578 반응식
[C:1]1([C:45]2[CH:50]=[CH:49][CH:48]=[CH:47][CH:46]=2)[CH:6]=[CH:5][CH:4]=[CH:3][C:2]=1[NH:7][C:8](=[O:44])[O:9][CH:10]1[CH2:15][CH2:14][N:13]([CH2:16][CH2:17][N:18]([C:20](=[O:43])[CH2:21][CH2:22][CH2:23][CH2:24][CH2:25][NH:26][C:27]2[CH:32]=[CH:31][C:30]([C:33](=[O:41])[N:34]([CH3:40])[CH2:35][CH2:36][CH2:37][NH:38][CH3:39])=[C:29]([Cl:42])[CH:28]=2)[CH3:19])[CH2:12][CH2:11]1.[F:51][C:52]([F:99])([F:98])[C:53]1[CH:54]=[C:55]([CH:91]=[C:92]([C:94]([F:97])([F:96])[F:95])[CH:93]=1)[C:56]([N:58]1[CH2:62][C@@:61]([CH2:70][CH2:71][N:72]2[CH2:77][CH2:76][C:75]3([C:85]4[C:80](=[CH:81][CH:82]=[CH:83][CH:84]=4)[CH2:79][C@@H:78]3[O:86][CH2:87][C:88](O)=[O:89])[CH2:74][CH2:73]2)([C:63]2[CH:68]=[CH:67][C:66]([F:69])=[CH:65][CH:64]=2)[O:60][CH2:59]1)=[O:57]>>[ClH:42].[ClH:42].[ClH:42].[C:1]1([C:45]2[CH:50]=[CH:49][CH:48]=[CH:47][CH:46]=2)[CH:6]=[CH:5][CH:4]=[CH:3][C:2]=1[NH:7][C:8](=[O:44])[O:9][CH:10]1[CH2:15][CH2:14][N:13]([CH2:16][CH2:17][N:18]([C:20](=[O:43])[CH2:21][CH2:22][CH2:23][CH2:24][CH2:25][NH:26][C:27]2[CH:32]=[CH:31][C:30]([C:33](=[O:41])[N:34]([CH2:35][CH2:36][CH2:37][N:38]([C:88](=[O:89])[CH2:87][O:86][C@@H:78]3[C:75]4([CH2:76][CH2:77][N:72]([CH2:71][CH2:70][C@:61]5([C:63]6[CH:68]=[CH:67][C:66]([F:69])=[CH:65][CH:64]=6)[O:60][CH2:59][N:58]([C:56](=[O:57])[C:55]6[CH:91]=[C:92]([C:94]([F:95])([F:96])[F:97])[CH:93]=[C:53]([C:52]([F:99])([F:51])[F:98])[CH:54]=6)[CH2:62]5)[CH2:73][CH2:74]4)[C:85]4[C:80](=[CH:81][CH:82]=[CH:83][CH:84]=4)[CH2:79]3)[CH3:39])[CH3:40])=[C:29]([Cl:42])[CH:28]=2)[CH3:19])[CH2:12][CH2:11]1
참가 물질실험 절차출처 및 근거반응 노트

참가 물질

3

반응물 2

HCID 666715051-{2-[{6-[(3-Chloro-4-{methyl[3-(methylamino)propyl]carbamoyl}phenyl)amino]hexanoyl}(methyl)amino]ethyl}piperidin-4-yl biphenyl-2-ylcarbamateHCID 86663420{[(2S)-1'-{2-[(5R)-3-[3,5-Bis(trifluoromethyl)benzoyl]-5-(4-fluorophenyl)-1,3-oxazolidin-5-yl]ethyl}-2,3-dihydrospiro[indene-1,4'-piperidin]-2-yl]oxy}acetic acid

생성물 1

HCID 86761912
1-(2-{[6-({4-[{3-[({[(2S)-1'-{2-[(5R)-3-[3,5-Bis(trifluoromethyl)benzoyl]-5-(4-fluorophenyl)-1,3-oxazolidin-5-yl]ethyl}-2,3-dihydrospiro[indene-1,4'-piperidin]-2-yl]oxy}acetyl)(methyl)amino]propyl}(methyl)carbamoyl]-3-chlorophenyl}amino)hexanoyl](methyl)amino}ethyl)piperidin-4-yl biphenyl-2-ylcarbamate trihydrochloride
수율 134.1%

실험 절차

The compound (92.0 mg, 0.130 mmol) obtained in Example 85c and the compound (108 mg, 0.156 mmol) obtained in Example 1j were used to give the title compound (65 mg; yield, 34%) as a white solid according to the method described in Example 80c.

출처 및 근거

ORD 기록
ord-8f8e71ba5b1e430f93784e1e9230f1b1
출처 데이터셋
uspto-grants-2013_07
DOI
10.6084/m9.figshare.5104873.v1
특허 번호
US08476253B2

반응 노트

불러오는 중…

이 페이지에서참가 물질실험 절차출처 및 근거반응 노트